Abstract: A treatment to differentially regulate the expression of genes related to irritable bowel syndrome is provided.

Abstract: The present invention provides novel DNA sequences, recombinant DNA (rDNA) molecules, processes for producing novel T-cell proteins expressed in T-cell development, the novel T-cell proteins in substantially pure form and antibodies which bind to the novel proteins. More particularly, it relates to novel DNA sequences expressed in appropriate hosts and the novel T-cell proteins produced in these hosts. The present invention also provides novel transmembrane proteins in substantially pure form, rDNA molecules encoding transmembrane proteins and processes for producing the novel transmembrane proteins.

Abstract: The present invention provides a novel cDNA sequence (Pem), a gene product protein (Seq. id No. 1), and uses for this novel cDNA Sequence and the Pem gene product. The DNA sequence and recombinant DNA molecules of this invention are characterized in that each codes for a novel protein having the following characteristics: (1) is expressed by T lymphoma cells, (2) is not expressed in normal thymus, activated spleen cells, gut associated lymphoid tissue, or bone marrow, and is not detectable in adult brain, liver, large intestine or ovary, (3) is expressed in immortalized or cancerous cell lines, and (4) is expressed in embryonic development.

Abstract: The present invention provides novel DNA sequences, recombinant DNA (rDNA) molecules, processes for producing novel T-cell proteins expressed in T-cell development, the novel T-cell proteins in substantially pure form and antibodies which bind to the novel proteins. More particularly, it relates to novel DNA sequences expressed in appropriate hosts and the novel T-cell proteins produced in these hosts. The present invention also provides novel transmembrane proteins in substantially pure form, rDNA molecules encoding transmembrane proteins and processes for producing the novel transmembrane proteins.

Abstract: Osteoprogenitor cells encapsulated in alginate and alternatively, additionally encapsulated in poly-L-lysine and/or agarose promote regeneration of bone at the site of implantation. The present invention provides a composition comprising osteoprogenitor cells embedded or encapsulated in alginate and the use of said microcapsules for the facilitation of bone regeneration.